FI1849470T4 - Syövän vastainen lääke sisältäen alfa,alfa,alfa-trifluoritymidiiniä ja tymidiinifosforylaasin estäjää - Google Patents
Syövän vastainen lääke sisältäen alfa,alfa,alfa-trifluoritymidiiniä ja tymidiinifosforylaasin estäjää Download PDFInfo
- Publication number
- FI1849470T4 FI1849470T4 FIEP06712292.9T FI06712292T FI1849470T4 FI 1849470 T4 FI1849470 T4 FI 1849470T4 FI 06712292 T FI06712292 T FI 06712292T FI 1849470 T4 FI1849470 T4 FI 1849470T4
- Authority
- FI
- Finland
- Prior art keywords
- cancer
- drug
- therapeutic
- dose
- day
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/042,059 US7799783B2 (en) | 2005-01-26 | 2005-01-26 | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor |
| JP2005165156 | 2005-06-06 | ||
| PCT/JP2006/301097 WO2006080327A1 (ja) | 2005-01-26 | 2006-01-25 | α，α，α－トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI1849470T4 true FI1849470T4 (fi) | 2024-03-22 |
Family
ID=36740357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP06712292.9T FI1849470T4 (fi) | 2005-01-26 | 2017-09-06 | Syövän vastainen lääke sisältäen alfa,alfa,alfa-trifluoritymidiiniä ja tymidiinifosforylaasin estäjää |
Country Status (21)
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| RU2394581C2 (ru) | 2005-01-26 | 2010-07-20 | Тайхо Фармасьютикал Ко., Лтд. | ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ |
| DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
| US8536188B2 (en) | 2007-04-25 | 2013-09-17 | Cyclacel Limited | Dosing regimens for treatment of proliferative disorders comprising administration of sapacitabine |
| AU2009207796B2 (en) | 2008-01-25 | 2014-03-27 | Grunenthal Gmbh | Pharmaceutical dosage form |
| AU2009243681B2 (en) | 2008-05-09 | 2013-12-19 | Grunenthal Gmbh | Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step |
| US20110065663A1 (en) * | 2008-05-15 | 2011-03-17 | Katholieke Universiteit Leuven, K.U. Leuven R&D | Anti-cancer combination therapy |
| AR077420A1 (es) | 2009-07-22 | 2011-08-24 | Gruenenthal Gmbh | Forma de dosificacion resistente a la manipulacion para opiaceos sensibles a la oxidacion |
| MX2012000317A (es) | 2009-07-22 | 2012-02-08 | Gruenenthal Gmbh | Forma de dosificacion de liberacion controlada extruida por fusion en caliente. |
| JP5933553B2 (ja) | 2010-09-02 | 2016-06-15 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | アニオン性ポリマーを含む不正使用抵抗性剤形 |
| NZ607392A (en) | 2010-09-02 | 2015-03-27 | Gruenenthal Chemie | Tamper resistant dosage form comprising inorganic salt |
| AR087359A1 (es) | 2011-07-29 | 2014-03-19 | Gruenenthal Gmbh | Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco |
| SI2736495T1 (sl) | 2011-07-29 | 2017-12-29 | Gruenenthal Gmbh | Tableta, odporna proti zlorabi, ki zagotavlja takojšnje sproščanje zdravila |
| SMT201800108T1 (it) * | 2011-08-16 | 2018-05-02 | Taiho Pharmaceutical Co Ltd | Agente antitumorale e metodo di previsione dell'effetto terapeutico per pazienti con cancro colorettale con kras mutato |
| TWI526210B (zh) * | 2012-02-15 | 2016-03-21 | Taiho Pharmaceutical Co Ltd | Oral pharmaceutical composition |
| TWI503122B (zh) * | 2012-02-15 | 2015-10-11 | Taiho Pharmaceutical Co Ltd | Oral administration of pharmaceutical compositions |
| EP2819656A1 (en) | 2012-02-28 | 2015-01-07 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
| JP6030119B2 (ja) | 2012-03-14 | 2016-11-24 | 日清ファルマ株式会社 | 含硫アミノ酸含有組成物 |
| TR201815502T4 (tr) | 2012-04-18 | 2018-11-21 | Gruenenthal Gmbh | Kurcalama veya dirençli ve doz boşalımına dirençli farmasötik dozaj formu. |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| EP2849756A1 (en) | 2012-05-16 | 2015-03-25 | Novartis AG | Dosage regimen for a pi-3 kinase inhibitor |
| AU2014245146B2 (en) * | 2013-03-27 | 2017-08-31 | Les Laboratoires Servier | Antitumor agent including irinotecan hydrochloride hydrate |
| AU2014245147B2 (en) * | 2013-03-27 | 2017-08-31 | Les Laboratoires Servier | Antitumor agent including low-dose irinotecan hydrochloride hydrate |
| NZ714014A (en) * | 2013-05-17 | 2017-06-30 | Taiho Pharmaceutical Co Ltd | Therapeutic effect prediction method for colorectal cancer patient in whom expression of tk1 protein has increased |
| CA2913209A1 (en) | 2013-05-29 | 2014-12-04 | Grunenthal Gmbh | Tamper resistant dosage form with bimodal release profile |
| US10154966B2 (en) | 2013-05-29 | 2018-12-18 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
| CN105682643B (zh) | 2013-07-12 | 2019-12-13 | 格吕伦塔尔有限公司 | 含有乙烯-醋酸乙烯酯聚合物的防篡改剂型 |
| DK3042669T3 (da) | 2013-09-06 | 2023-06-12 | Taiho Pharmaceutical Co Ltd | Antitumormiddel og forstærker af antitumorvirkning |
| CN105934241B (zh) | 2013-11-26 | 2020-06-05 | 格吕伦塔尔有限公司 | 通过低温研磨制备粉末状药物组合物 |
| AU2015261060A1 (en) | 2014-05-12 | 2016-11-03 | Grunenthal Gmbh | Tamper resistant immediate release capsule formulation comprising Tapentadol |
| CN106456550A (zh) | 2014-05-26 | 2017-02-22 | 格吕伦塔尔有限公司 | 避免乙醇剂量倾泻的多颗粒 |
| HK1246173A1 (zh) | 2015-04-24 | 2018-09-07 | Grünenthal GmbH | 具有立即释放和对溶剂萃取的抗性的抗篡改剂型 |
| EP3346991A1 (en) | 2015-09-10 | 2018-07-18 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
| JP6871868B2 (ja) * | 2016-01-08 | 2021-05-19 | 大鵬薬品工業株式会社 | 免疫調節剤を含有する抗腫瘍剤及び抗腫瘍効果増強剤 |
| KR102412690B1 (ko) | 2016-02-05 | 2022-06-23 | 다이호야쿠힌고교 가부시키가이샤 | 중증 신장 기능 장애를 갖는 암 환자에 대한 치료 방법 |
| EP3730935A4 (en) | 2017-12-22 | 2022-02-23 | Taiho Pharmaceutical Co., Ltd. | METHOD OF DETECTING ANALOGUES OF TRIFLURIDIN AND/OR TIPIRACIL |
| US10866219B2 (en) | 2017-12-22 | 2020-12-15 | Taiho Pharmaceutical Co., Ltd. | Method for detecting trifluridine- and/or tipiracil-related substance |
| US10816517B2 (en) | 2018-01-05 | 2020-10-27 | Taiho Pharmaceutical Co., Ltd. | Method for detecting trifluridine-related substance by high-performance liquid chromatography |
| WO2019135405A1 (ja) | 2018-01-05 | 2019-07-11 | 大鵬薬品工業株式会社 | トリフルリジン由来の類縁物質の検出方法 |
| US20260021045A1 (en) * | 2024-07-17 | 2026-01-22 | Jnd Therapeutics, Inc. | Methods and formulations for treatment of liver cancer using trifluridine |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69629156T2 (de) * | 1995-03-29 | 2004-05-06 | Taiho Pharmaceutical Co. Ltd. | Uracilderivate und diese enthaltende antitumoreffekt-verstärker sowie antitumormittel |
| CA2238331C (en) * | 1996-09-24 | 2003-02-25 | Taiho Pharmaceutical Co., Ltd. | Cancerous metastasis inhibitors containing uracil derivatives |
| RU2394581C2 (ru) | 2005-01-26 | 2010-07-20 | Тайхо Фармасьютикал Ко., Лтд. | ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ |
-
2006
- 2006-01-25 RU RU2007132181/15A patent/RU2394581C2/ru active
- 2006-01-25 PL PL06712292.9T patent/PL1849470T5/pl unknown
- 2006-01-25 AU AU2006209547A patent/AU2006209547C1/en not_active Expired
- 2006-01-25 JP JP2007500529A patent/JP5576591B2/ja not_active Expired - Lifetime
- 2006-01-25 LT LTEP06712292.9T patent/LT1849470T/lt unknown
- 2006-01-25 WO PCT/JP2006/301097 patent/WO2006080327A1/ja not_active Ceased
- 2006-01-25 DK DK06712292.9T patent/DK1849470T4/da active
- 2006-01-25 HU HUE06712292A patent/HUE033306T2/hu unknown
- 2006-01-25 EP EP06712292.9A patent/EP1849470B2/en not_active Expired - Lifetime
- 2006-01-25 ES ES06712292T patent/ES2630002T5/es not_active Expired - Lifetime
- 2006-01-25 CA CA002594713A patent/CA2594713A1/en not_active Withdrawn
- 2006-01-25 SI SI200632192T patent/SI1849470T2/sl unknown
- 2006-01-25 PT PT67122929T patent/PT1849470T/pt unknown
- 2006-01-26 TW TW095103114A patent/TWI362265B/zh active
-
2007
- 2007-07-19 KR KR1020077016492A patent/KR101468216B1/ko not_active Expired - Lifetime
-
2017
- 2017-07-28 LT LTPA2017024 patent/LTC1849470I2/lt unknown
- 2017-08-01 HU HUS1700032C patent/HUS1700032I1/hu unknown
- 2017-08-03 BE BE2017C028C patent/BE2017C028I2/fr unknown
- 2017-08-08 FR FR17C1028C patent/FR17C1028I2/fr active Active
- 2017-08-08 NL NL300889C patent/NL300889I2/nl unknown
- 2017-09-06 FI FIEP06712292.9T patent/FI1849470T4/fi active
- 2017-09-07 CY CY2017029C patent/CY2017029I1/el unknown
- 2017-09-07 CY CY20171100947T patent/CY1119393T1/el unknown
- 2017-09-29 LU LU00036C patent/LUC00036I2/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI1849470T4 (fi) | Syövän vastainen lääke sisältäen alfa,alfa,alfa-trifluoritymidiiniä ja tymidiinifosforylaasin estäjää | |
| JP2006515883A5 (cg-RX-API-DMAC10.html) | ||
| US20110015135A1 (en) | Antitumoral Treatments | |
| JP2009539769A5 (cg-RX-API-DMAC10.html) | ||
| MX2023003564A (es) | Compuestos y su uso en el tratamiento del cancer. | |
| TWI641374B (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| ES2625492T3 (es) | Combinación terapéutica que comprende un inhibidor de Cdc7 y un agente antineoplásico | |
| JP2019524713A5 (cg-RX-API-DMAC10.html) | ||
| JP2023065622A (ja) | 重度腎機能障害を有する癌患者に対する治療方法 | |
| CN101107001A (zh) | 配合有α,α,α-三氟胸苷和胸苷磷酸化酶抑制剂的抗癌剂 | |
| ES2824400T3 (es) | Agente antitumoral que incluye clorhidrato de irinotecán hidratado | |
| Choi et al. | A case of pneumatosis intestinalis associated with sunitinib treatment for renal cell carcinoma | |
| JP2011514356A5 (cg-RX-API-DMAC10.html) | ||
| EP2205263A1 (en) | Improved antitumoral treatments | |
| JP6458007B2 (ja) | 抗腫瘍性白金錯体を含有する抗腫瘍剤及び抗腫瘍効果増強剤 | |
| Chang et al. | Methotrexate and leucovorin double-modulated 5-fluorouracil combined with cisplatin (MPFL) in metastatic/recurrent head and neck cancer | |
| JP2015199678A (ja) | ラパチニブトシル酸塩水和物を含有する抗腫瘍剤及び抗腫瘍効果増強剤 | |
| JPWO2015152409A1 (ja) | タキサン系化合物を含有する抗腫瘍剤及び抗腫瘍効果増強剤 | |
| JP2015199677A (ja) | ノギテカン塩酸塩を含有する抗腫瘍剤及び抗腫瘍効果増強剤 | |
| JP2013166702A (ja) | キナーゼ阻害剤を組み合わせた抗腫瘍剤 | |
| NZ740252A (en) | Antitumor agent including low-dose irinotecan hydrochloride hydrate | |
| HK1177889B (en) | Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent | |
| CN103933539A (zh) | 一种含有四环素的药物组合物及其应用 |